Validity of rapid urease test using swab of gastric mucus to mucosal forceps and 13 C-urease breath test: a multicenter prospective observational study.


Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
09 Aug 2024
Historique:
received: 15 03 2024
accepted: 30 07 2024
medline: 10 8 2024
pubmed: 10 8 2024
entrez: 9 8 2024
Statut: epublish

Résumé

Theoretically, a rapid urease test (RUT) using a swab of the gastric wall (Swab-RUT) for Helicobacter pylori (H. pylori) is safe. However, the validity and utility of Swab-RUT remain unclear. Therefore, we assessed the validity and utility of Swab-RUT compared to RUT using mucosal forceps of the gastric wall (Forceps-RUT) and This study was a multicenter prospective observational study. When the examinees were suspected of H. pylori infection during esophagogastroduodenoscopy, we performed Swab-RUT and Forceps-RUT continuously. When the examinees were not suspected of H. pylori infection, we performed Swab-RUT alone. We validated the status of H. pylori infection using UBT. Ninety-four examinees were enrolled from four institutions between May 2016 and December 2020 (median age [range], 56.5 [26-88] years). In this study, the sensitivity, specificity, and accuracy of Swab-RUT to UBT were 0.933 (95% confidence interval: 0.779-0.992), 0.922 (0.827-0.974), and 0.926 (0.853-0.970), respectively. The Kappa coefficient of Swab-RUT to UBT was 0.833, and that of Swab-RUT to forceps-RUT was 0.936. No complications were observed in this study. Swab-RUT is a valid examination for the status of H. pylori infection compared to the conventional Forceps-RUT.

Sections du résumé

BACKGROUND BACKGROUND
Theoretically, a rapid urease test (RUT) using a swab of the gastric wall (Swab-RUT) for Helicobacter pylori (H. pylori) is safe. However, the validity and utility of Swab-RUT remain unclear. Therefore, we assessed the validity and utility of Swab-RUT compared to RUT using mucosal forceps of the gastric wall (Forceps-RUT) and
METHODS METHODS
This study was a multicenter prospective observational study. When the examinees were suspected of H. pylori infection during esophagogastroduodenoscopy, we performed Swab-RUT and Forceps-RUT continuously. When the examinees were not suspected of H. pylori infection, we performed Swab-RUT alone. We validated the status of H. pylori infection using UBT.
RESULTS RESULTS
Ninety-four examinees were enrolled from four institutions between May 2016 and December 2020 (median age [range], 56.5 [26-88] years). In this study, the sensitivity, specificity, and accuracy of Swab-RUT to UBT were 0.933 (95% confidence interval: 0.779-0.992), 0.922 (0.827-0.974), and 0.926 (0.853-0.970), respectively. The Kappa coefficient of Swab-RUT to UBT was 0.833, and that of Swab-RUT to forceps-RUT was 0.936. No complications were observed in this study.
CONCLUSIONS CONCLUSIONS
Swab-RUT is a valid examination for the status of H. pylori infection compared to the conventional Forceps-RUT.

Identifiants

pubmed: 39123129
doi: 10.1186/s12876-024-03344-2
pii: 10.1186/s12876-024-03344-2
doi:

Substances chimiques

Urease EC 3.5.1.5
Carbon Isotopes 0

Types de publication

Journal Article Observational Study Multicenter Study Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

258

Informations de copyright

© 2024. The Author(s).

Références

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660 pubmed: 33538338
Morgan E, Arnold M, Camargo MC, Gini A, Kunzmann AT, Matsuda T, Meheus F, Verhoeven RHA, Vignat J, Laversanne M, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study. EClinicalMedicine. 2022;47:101404.
doi: 10.1016/j.eclinm.2022.101404 pubmed: 35497064 pmcid: 9046108
Helicobacter C, Collaborative G. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49(3):347–53.
doi: 10.1136/gut.49.3.347
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.
doi: 10.1016/S1470-2045(12)70137-7 pubmed: 22575588
Gonzalez CA, Megraud F, Buissonniere A, Lujan Barroso L, Agudo A, Duell EJ, Boutron-Ruault MC, Clavel-Chapelon F, Palli D, Krogh V, et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Ann Oncol. 2012;23(5):1320–4.
doi: 10.1093/annonc/mdr384 pubmed: 21917738
Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, Graham DY. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016;150(5):1113–e11241115.
doi: 10.1053/j.gastro.2016.01.028 pubmed: 26836587
Tsuda M, Asaka M, Kato M, Matsushima R, Fujimori K, Akino K, Kikuchi S, Lin Y, Sakamoto N. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22(5).
Chiang TH, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, Chen YR, Chuang SL, Shieh CF, Liu CY, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70(2):243–50.
pubmed: 32792335
Thiede C, Morgner A, Alpen B, Wundisch T, Herrmann J, Ritter M, Ehninger G, Stolte M, Bayerdorffer E, Neubauer A. What role does Helicobacter pylori eradication play in gastric MALT and gastric MALT lymphoma? Gastroenterology. 1997;113(6 Suppl):S61–64.
doi: 10.1016/S0016-5085(97)80014-5 pubmed: 9394762
Suzuki T, Matsushima M, Masui A, Watanabe K, Takagi A, Ogawa Y, Shirai T, Mine T. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial. Am J Gastroenterol. 2005;100(6):1265–70.
doi: 10.1111/j.1572-0241.2005.41641.x pubmed: 15929755
Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, Lee YT, Chan CS, Li EK, Woo J. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350(9083):975–9.
doi: 10.1016/S0140-6736(97)04523-6 pubmed: 9329511
Garza-Gonzalez E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014;20(6):1438–49.
doi: 10.3748/wjg.v20.i6.1438 pubmed: 24587620 pmcid: 3925853
Matsumoto H, Shiotani A, Nishibayashi H, Kamada T, Kimura T, Fujimura Y, Nakato R, Murao T, Fujita M, Haruma K. Molecular detection of H. Pylori using adherent gastric mucous to biopsy forceps. Helicobacter. 2016;21(6):548–53.
doi: 10.1111/hel.12310 pubmed: 27061611
Noh CK, Lee GH, Park JW, Roh J, Han JH, Lee E, Park B, Lim SG, Shin SJ, Cheong JY, et al. Diagnostic accuracy of sweeping method compared to conventional sampling in rapid urease test for Helicobacter pylori detection in atrophic mucosa. Sci Rep. 2020;10(1):18483.
doi: 10.1038/s41598-020-75528-1 pubmed: 33116260 pmcid: 7595103
Soh H, Kim N, Moon J, Lee HM, Kim B, Cho SJ, Kim SG, Chung H. Gastric mucosal swab as an alternative to biopsy for Helicobacter pylori detection. Helicobacter. 2023;28(3):e12980.
doi: 10.1111/hel.12980 pubmed: 37026561
Kamada T, Haruma K, Inoue K, Shiotani A. [Helicobacter pylori infection and endoscopic gastritis -Kyoto classification of gastritis]. Nihon Shokakibyo Gakkai Zasshi. 2015;112(6):982–93.
pubmed: 26050720
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.
doi: 10.2307/2529310 pubmed: 843571
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48(3):452–8.
doi: 10.1038/bmt.2012.244

Auteurs

Takaaki Yoshikawa (T)

Department of Gastroenterology and Hepatology, Medical Research Institute Kitano Hospital, PIIF Tazuke Kofukai, 2-4-20, Ohgimachi, Kita-ku, Osaka, 530-8480, Japan. tk_yoshi@kuhp.kyoto-u.ac.jp.

Atsushi Yamauchi (A)

Department of Gastroenterology and Hepatology, Medical Research Institute Kitano Hospital, PIIF Tazuke Kofukai, 2-4-20, Ohgimachi, Kita-ku, Osaka, 530-8480, Japan.

Tadayuki Kou (T)

Department of Gastroenterology and Hepatology, Medical Research Institute Kitano Hospital, PIIF Tazuke Kofukai, 2-4-20, Ohgimachi, Kita-ku, Osaka, 530-8480, Japan.

Takahisa Murao (T)

Department of Gastroenterology and Hepatology, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Okayama, Japan.
Department of Health Care Medicine, Kawasaki Medical School General Medical Center, 2-6-1, Nakasange, Kita-Ku, Okayama, 700-8505, Japan.

Tomoari Kamada (T)

Department of Health Care Medicine, Kawasaki Medical School General Medical Center, 2-6-1, Nakasange, Kita-Ku, Okayama, 700-8505, Japan.

Mitsuhiko Suehiro (M)

Department of General Internal Medicine 2, Kawasaki Medical School General Medical Center, 2-6-1, Nakasange, Kita-Ku, Okayama, 700-8505, Japan.

Koichiro Kawano (K)

Department of Gastroenterology and Hepatology, Hyogo Prefectural Awaji Medical Center, 1-1-137, Shioya, Sumoto City, 656-0021, Hyogo, Japan.

Ken Haruma (K)

Department of General Internal Medicine 2, Kawasaki Medical School General Medical Center, 2-6-1, Nakasange, Kita-Ku, Okayama, 700-8505, Japan.

Shujiro Yazumi (S)

Department of Gastroenterology and Hepatology, Medical Research Institute Kitano Hospital, PIIF Tazuke Kofukai, 2-4-20, Ohgimachi, Kita-ku, Osaka, 530-8480, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH